Dong-E-E-Jiao (SHE:000423) expects an attributable profit of between 1.5 billion yuan and 1.6 billion yuan for the year 2024, up from 1.15 billion yuan a year prior, a Friday bourse filing by parent China Resources Pharmaceutical Group (HKG:3320) said.
The pharmaceutical company's higher anticipated profit was mainly due to a steady growth in operating performance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。